Clinical trial · Interventional
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
NCT00064376CI-TRIAL-00031412completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| paricalcitol | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 100 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Clinical diagnosis of myelodysplastic syndromes according to the modified FAB classification * Confirmed by bone marrow aspiration showing blast and promyelocyte count no greater than 30% of the bone marrow differential * Patients with refractory anemia with ringed sideroblasts are eligible provided there was no response to a 3-week course of prior high-dose pyridoxine PATIENT CHARACTERISTICS: Age * 25 to 100 Performance status * Karnofsky 60-100% Life expectancy * At least 12 weeks Hematopoietic * See Disease Characteristics Hepatic * Bilirubin less than 2.0 mg/dL Renal * Creatinine less than 2.5 mg/dL * Calcium normal Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior sensitivity to paricalcitol or any component of its formulation * No prior cholecalciferol toxicity * No other concurrent acute illness PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * More than 5 weeks since prior chemotherapy Endocrine therapy * Not specified Radiotherapy * More than 5 weeks since prior radiotherapy Surgery * Prior recent surgery allowed, if fully recovered Other * More than 5 weeks since prior megadose vitamins * No concurrent cholecalciferol, phosphate, calcium, or cholestyramine * No concurrent digoxin
References
Publications (0)
Data not yet available
No reference posted for this study.